Explain this page
Arphra AIPlain-English read on Revolution Medicines, Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $165.75 (-1.81%)
Candlestick · 1Y
Open in chart workstation →RVMD
162.99+307.17%H 166.50L 34.00MA50 146.50MA200 95.18Avg vol 2.8M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.49% | +3.92% | +11.30% | +76.60% | +107.76% | +111.78% | +321.39% | +578.26% | +415.85% | +483.68% | +483.68% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$168.68
11 sh
Bid
$155.28
2 sh
Ask
$180.36
2 sh
Spread
$25.080
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Consumer Cyclical+1.71%
- Technology+1.69%
- Industrials+1.33%
- Utilities+0.95%
- Basic Materials+0.94%
- Financial Services+0.87%
- Consumer Defensive+0.51%
- Communication Services+0.48%
- Energy-0.57%
- Healthcare-0.94%
- Real Estate-1.06%
Top industries (issuer's industry highlighted)
- Biotechnology+5.59%
- Financial - Mortgages+6.51%
- Furnishings, Fixtures & Appliances+4.84%
- Business Equipment & Supplies+4.13%
- Hardware, Equipment & Parts+4.01%
- Construction+3.63%
- Auto - Recreational Vehicles+3.62%
- Real Estate - Development+3.61%
- Home Improvement+3.55%
- Electronic Gaming & Multimedia+3.45%
- Travel Services+3.12%
- Paper, Lumber & Forest Products+3.05%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasibzacks.com·Jun 24, 2026
- Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.globenewswire.com·Jun 22, 2026
- Revolution Medicines: Strong Data, Big Market (Rating Upgrade)seekingalpha.com·Jun 13, 2026
- Can Revolution Medicines Be a Game-Changer Stock?fool.com·Jun 11, 2026
- Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?zacks.com·Jun 05, 2026
- Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.fool.com·Jun 05, 2026
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancerglobenewswire.com·May 06, 2026
- Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progressglobenewswire.com·May 06, 2026
Recent analyst activity
DB- Jun 22, 2026GradeOutperform → OutperformRBC Capital Reiterates Outperform Rating on Revolution (RVMD)RBC Capital
- Jun 09, 2026PT$175.00UBS Reiterates Buy Rating on Revolution (RVMD) Following Trial Data ReleaseUBS
- Jun 09, 2026GradeBuy → BuyUBS Reiterates Buy Rating on Revolution (RVMD) Following Trial Data ReleaseUBS
- Jun 02, 2026PT$182.00Revolution (RVMD) PT Raised to $182 at RBC CapitalRBC Capital
- Jun 02, 2026GradeOutperform → OutperformRevolution (RVMD) PT Raised to $182 at RBC CapitalRBC Capital
- Jun 01, 2026PT$195.00Revolution Medicines price target raised to $195 from $169 at H.C. WainwrightH.C. Wainwright
- Jun 01, 2026GradeBuy → BuyRevolution Medicines price target raised to $195 from $169 at H.C. WainwrightH.C. Wainwright
- Jun 01, 2026GradeOutperform → OutperformWedbush reiterates Outperform on Revolution Medicines after ASCO dataWedbush
- Jun 01, 2026GradeBuy → BuyTD Cowen Reiterates Buy Rating and Top Pick on Revolution (RVMD)Cowen & Co.
- Jun 01, 2026GradeOutperform → OutperformRevolution Medicines price target raised to $195 from $165 at OppenheimerOppenheimer
- Jun 01, 2026PT$195.00Revolution Medicines price target raised to $195 from $165 at OppenheimerOppenheimer
Financial scores
DBJun 23, 2026Altman Z
24.81
Safe
≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress
Piotroski F
1/9
Weak
≥ 7 strong · 4–6 average · < 4 weak
Peers
No peer list available for RVMD.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|